Prediction of Response and Survival Following Treatment with Azacitidine for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation
To provide long-term outcome data and predictors for response and survival, we retrospectively analyzed all 151 patients with relapse of myeloid neoplasms after allogeneic hematopoietic stem cell transplantation (allo-HSCT) who were uniformly treated with first-line azacitidine (Aza) salvage therapy...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464210/ https://www.ncbi.nlm.nih.gov/pubmed/32806572 http://dx.doi.org/10.3390/cancers12082255 |
_version_ | 1783577311589695488 |
---|---|
author | Rautenberg, Christina Bergmann, Anika Germing, Ulrich Fischermanns, Caroline Pechtel, Sabrina Kaivers, Jennifer Jäger, Paul Schuler, Esther Haas, Rainer Kobbe, Guido Schroeder, Thomas |
author_facet | Rautenberg, Christina Bergmann, Anika Germing, Ulrich Fischermanns, Caroline Pechtel, Sabrina Kaivers, Jennifer Jäger, Paul Schuler, Esther Haas, Rainer Kobbe, Guido Schroeder, Thomas |
author_sort | Rautenberg, Christina |
collection | PubMed |
description | To provide long-term outcome data and predictors for response and survival, we retrospectively analyzed all 151 patients with relapse of myeloid neoplasms after allogeneic hematopoietic stem cell transplantation (allo-HSCT) who were uniformly treated with first-line azacitidine (Aza) salvage therapy at our center. Patients were treated for molecular (39%) or hematologic relapse (61%), with a median of 5 cycles of Aza and at least one donor lymphocyte infusion in 70% of patients. Overall response was 46%, with 41% achieving complete (CR) and 5% achieving partial remission. CR was achieved after a median of 4 cycles and lasted for a median of 11 months (range 0.9 to 120 months). With a median follow-up of 22 months (range: 1 to 122 months), the 2-year survival rate was 38% ± 9%, including 17 patients with ongoing remission for >5 years. Based on results from multivariate analyses, molecular relapse and time to relapse were integrated into a score, clearly dividing patients into 3 subgroups with CR rates of 71%, 39%, and 29%; and 2-year survival rates of 64%, 38%, and 27%, respectively. In the subgroup of MDS and secondary AML, receiving upfront transplantation was associated with superior response and survival, and therefore pretransplant strategy was integrated together with relapse type into a MDS–sAML-specific score. Overall, Aza enables meaningful responses and long-term survival, which is a predictable with a simple-to-use scoring system. |
format | Online Article Text |
id | pubmed-7464210 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74642102020-09-04 Prediction of Response and Survival Following Treatment with Azacitidine for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation Rautenberg, Christina Bergmann, Anika Germing, Ulrich Fischermanns, Caroline Pechtel, Sabrina Kaivers, Jennifer Jäger, Paul Schuler, Esther Haas, Rainer Kobbe, Guido Schroeder, Thomas Cancers (Basel) Article To provide long-term outcome data and predictors for response and survival, we retrospectively analyzed all 151 patients with relapse of myeloid neoplasms after allogeneic hematopoietic stem cell transplantation (allo-HSCT) who were uniformly treated with first-line azacitidine (Aza) salvage therapy at our center. Patients were treated for molecular (39%) or hematologic relapse (61%), with a median of 5 cycles of Aza and at least one donor lymphocyte infusion in 70% of patients. Overall response was 46%, with 41% achieving complete (CR) and 5% achieving partial remission. CR was achieved after a median of 4 cycles and lasted for a median of 11 months (range 0.9 to 120 months). With a median follow-up of 22 months (range: 1 to 122 months), the 2-year survival rate was 38% ± 9%, including 17 patients with ongoing remission for >5 years. Based on results from multivariate analyses, molecular relapse and time to relapse were integrated into a score, clearly dividing patients into 3 subgroups with CR rates of 71%, 39%, and 29%; and 2-year survival rates of 64%, 38%, and 27%, respectively. In the subgroup of MDS and secondary AML, receiving upfront transplantation was associated with superior response and survival, and therefore pretransplant strategy was integrated together with relapse type into a MDS–sAML-specific score. Overall, Aza enables meaningful responses and long-term survival, which is a predictable with a simple-to-use scoring system. MDPI 2020-08-12 /pmc/articles/PMC7464210/ /pubmed/32806572 http://dx.doi.org/10.3390/cancers12082255 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Rautenberg, Christina Bergmann, Anika Germing, Ulrich Fischermanns, Caroline Pechtel, Sabrina Kaivers, Jennifer Jäger, Paul Schuler, Esther Haas, Rainer Kobbe, Guido Schroeder, Thomas Prediction of Response and Survival Following Treatment with Azacitidine for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation |
title | Prediction of Response and Survival Following Treatment with Azacitidine for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation |
title_full | Prediction of Response and Survival Following Treatment with Azacitidine for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation |
title_fullStr | Prediction of Response and Survival Following Treatment with Azacitidine for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation |
title_full_unstemmed | Prediction of Response and Survival Following Treatment with Azacitidine for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation |
title_short | Prediction of Response and Survival Following Treatment with Azacitidine for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation |
title_sort | prediction of response and survival following treatment with azacitidine for relapse of acute myeloid leukemia and myelodysplastic syndromes after allogeneic hematopoietic stem cell transplantation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464210/ https://www.ncbi.nlm.nih.gov/pubmed/32806572 http://dx.doi.org/10.3390/cancers12082255 |
work_keys_str_mv | AT rautenbergchristina predictionofresponseandsurvivalfollowingtreatmentwithazacitidineforrelapseofacutemyeloidleukemiaandmyelodysplasticsyndromesafterallogeneichematopoieticstemcelltransplantation AT bergmannanika predictionofresponseandsurvivalfollowingtreatmentwithazacitidineforrelapseofacutemyeloidleukemiaandmyelodysplasticsyndromesafterallogeneichematopoieticstemcelltransplantation AT germingulrich predictionofresponseandsurvivalfollowingtreatmentwithazacitidineforrelapseofacutemyeloidleukemiaandmyelodysplasticsyndromesafterallogeneichematopoieticstemcelltransplantation AT fischermannscaroline predictionofresponseandsurvivalfollowingtreatmentwithazacitidineforrelapseofacutemyeloidleukemiaandmyelodysplasticsyndromesafterallogeneichematopoieticstemcelltransplantation AT pechtelsabrina predictionofresponseandsurvivalfollowingtreatmentwithazacitidineforrelapseofacutemyeloidleukemiaandmyelodysplasticsyndromesafterallogeneichematopoieticstemcelltransplantation AT kaiversjennifer predictionofresponseandsurvivalfollowingtreatmentwithazacitidineforrelapseofacutemyeloidleukemiaandmyelodysplasticsyndromesafterallogeneichematopoieticstemcelltransplantation AT jagerpaul predictionofresponseandsurvivalfollowingtreatmentwithazacitidineforrelapseofacutemyeloidleukemiaandmyelodysplasticsyndromesafterallogeneichematopoieticstemcelltransplantation AT schuleresther predictionofresponseandsurvivalfollowingtreatmentwithazacitidineforrelapseofacutemyeloidleukemiaandmyelodysplasticsyndromesafterallogeneichematopoieticstemcelltransplantation AT haasrainer predictionofresponseandsurvivalfollowingtreatmentwithazacitidineforrelapseofacutemyeloidleukemiaandmyelodysplasticsyndromesafterallogeneichematopoieticstemcelltransplantation AT kobbeguido predictionofresponseandsurvivalfollowingtreatmentwithazacitidineforrelapseofacutemyeloidleukemiaandmyelodysplasticsyndromesafterallogeneichematopoieticstemcelltransplantation AT schroederthomas predictionofresponseandsurvivalfollowingtreatmentwithazacitidineforrelapseofacutemyeloidleukemiaandmyelodysplasticsyndromesafterallogeneichematopoieticstemcelltransplantation |